Aspirin for MI primary prevention
Executive Summary
Use of aspirin for primary prevention of myocardial infarction will be considered by FDA's Cardiovascular & Renal Drugs Advisory Committee in consultation with Nonprescription Drugs Advisory Committee on Dec. 8. Bayer asked FDA in a Feb. 11 citizen petition to allow the indication based on a meta-analysis of five studies showing a 32% reduction in MI in patients who had not previously had a cardiovascular event. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8:30 a.m. [To 1watch a webcast of the meeting, go to FDAAdvisoryCommittee.com]...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.